Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Published Date: 20 Jun 2026

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

Read Full News

Latest News

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Inside the Major Findings From the NHS-Galleri Trial

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

Todays Updates

Tailoring Prostate Cancer Care in Men With Limited Longevity

Not every man with prostate cancer benefits from aggressive therapy. Drs Timothy Daskivich and John Leppert explore how to avoid overtreatment in men with limited longevity.

Older Man With Lyme Neuroborreliosis After Tick Bite

Facial palsy, encephalitis, and cerebrospinal fluid abnormalities ultimately indicated Lyme neuroborreliosis, despite early doxycycline treatment.

Families Traveling for Uveitis Screenings Face Higher Costs

Patients who lived more than 30 miles away from their specialists had median annual expenses over $400 in Tennessee and over $300 in California.

US FDA Advisers Vote in Favor of Moderna's Flu Vaccine

The U.S. Food ⁠and Drug Administration's ⁠advisers on Thursday backed ⁠approval ‌of Moderna's flu vaccine in adults aged 50 and ‌older, saying its benefits outweigh ‌the...

Congo Says Number Of Confirmed Ebola Cases Rises to 896

The number of confirmed Ebola ⁠cases in the Democratic Republic of Congo ⁠has increased to 896, including 232 ⁠deaths, government ‌data showed late on...

Australia, Last Continent Without H5 Bird Flu, Detects First Suspected Case

Australia has detected its first suspected mainland case of H5N1 bird flu in a remote part of the country's southwest, ⁠authorities said on Friday.

Sri Lanka Battles Surge in Dengue Fever, With More Than 44,000 Cases So Far This Year

Sri Lanka is battling the worst outbreak of mosquito-borne dengue fever in years, with more than ⁠44,000 cases and 28 deaths recorded since January, an official said on...

Todays Updates

Tailoring Prostate Cancer Care in Men With Limited Longevity

Not every man with prostate cancer benefits from aggressive therapy. Drs Timothy Daskivich and John Leppert explore how to avoid overtreatment in men with limited longevity.

Older Man With Lyme Neuroborreliosis After Tick Bite

Facial palsy, encephalitis, and cerebrospinal fluid abnormalities ultimately indicated Lyme neuroborreliosis, despite early doxycycline treatment.

Families Traveling for Uveitis Screenings Face Higher Costs

Patients who lived more than 30 miles away from their specialists had median annual expenses over $400 in Tennessee and over $300 in California.

US FDA Advisers Vote in Favor of Moderna's Flu Vaccine

The U.S. Food ⁠and Drug Administration's ⁠advisers on Thursday backed ⁠approval ‌of Moderna's flu vaccine in adults aged 50 and ‌older, saying its benefits outweigh ‌the...

Congo Says Number Of Confirmed Ebola Cases Rises to 896

The number of confirmed Ebola ⁠cases in the Democratic Republic of Congo ⁠has increased to 896, including 232 ⁠deaths, government ‌data showed late on...

Australia, Last Continent Without H5 Bird Flu, Detects First Suspected Case

Australia has detected its first suspected mainland case of H5N1 bird flu in a remote part of the country's southwest, ⁠authorities said on Friday.

Sri Lanka Battles Surge in Dengue Fever, With More Than 44,000 Cases So Far This Year

Sri Lanka is battling the worst outbreak of mosquito-borne dengue fever in years, with more than ⁠44,000 cases and 28 deaths recorded since January, an official said on...

Latest News

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

News All Time

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

Women with ovarian cancer who fast shortly before and after chemotherapy have lower insulin levels, stronger tumor responses, and longer progression-free survival in a small randomized trial.

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Recommended News For You

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

Prostate cancer relapse after radiotherapy is strongly predicted by biological markers.

How wildfires pose challenges to cancer care

CAR T-Cell Therapy for Kidney Cancer Builds on Efficacy Record

What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care

Routine breast cancer screening can bring better outcomes for patients

Study links persistent fatigue in breast cancer survivors to increased inflammation

Recommended Articles For You

Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment 

Unlocking the Potential of Leukemia Treatment: A New Hope for Patients 

Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives 

The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy

2.

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

3.

CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group

4.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

5.

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.

1.

Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?

2.

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients

3.

The Role of Calcium Corrections in Accurate Blood Test Results 

4.

Oncological Surgery Today: Personalized, Interdisciplinary Approaches to Cancer Care

5.

CAR-T Therapy in Blood Cancers: Mechanisms, Efficacy, and Clinical Integration

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Understanding the causes of anemia in adults beyond nutritional deficiencies

2.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

3.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

4.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

5.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot